437 related articles for article (PubMed ID: 22361765)
1. Antimicrobial activities against biofilm formed by Proteus mirabilis isolates from wound and urinary tract infections.
Wasfi R; Abd El-Rahman OA; Mansour LE; Hanora AS; Hashem AM; Ashour MS
Indian J Med Microbiol; 2012; 30(1):76-80. PubMed ID: 22361765
[TBL] [Abstract][Full Text] [Related]
2. Effects of ceftazidime and ciprofloxacin on biofilm formation in Proteus mirabilis rods.
Kwiecińska-Piróg J; Bogiel T; Gospodarek E
J Antibiot (Tokyo); 2013 Oct; 66(10):593-7. PubMed ID: 23801185
[TBL] [Abstract][Full Text] [Related]
3. [Proteus mirabilis isolated from urine, resistance to antibiotics and biofilm formation].
Cernohorská L; Chvílová E
Klin Mikrobiol Infekc Lek; 2011 Jun; 17(3):81-5. PubMed ID: 21780025
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic resistance pattern among biofilm producing and non producing Proteus strains isolated from hospitalized patients; matter of hospital hygiene and antimicrobial stewardship.
Shikh-Bardsiri H; Shakibaie MR
Pak J Biol Sci; 2013 Nov; 16(22):1496-502. PubMed ID: 24511691
[TBL] [Abstract][Full Text] [Related]
5. Potential Probiotics Bacillus subtilis KATMIRA1933 and Bacillus amyloliquefaciens B-1895 Co-Aggregate with Clinical Isolates of Proteus mirabilis and Prevent Biofilm Formation.
Algburi A; Alazzawi SA; Al-Ezzy AIA; Weeks R; Chistyakov V; Chikindas ML
Probiotics Antimicrob Proteins; 2020 Dec; 12(4):1471-1483. PubMed ID: 31989448
[TBL] [Abstract][Full Text] [Related]
6. Virulence factors in Proteus bacteria from biofilm communities of catheter-associated urinary tract infections.
Hola V; Peroutkova T; Ruzicka F
FEMS Immunol Med Microbiol; 2012 Jul; 65(2):343-9. PubMed ID: 22533980
[TBL] [Abstract][Full Text] [Related]
7. Clinical epidemiology of ciprofloxacin-resistant Proteus mirabilis isolated from urine samples of hospitalised patients.
Saito R; Okugawa S; Kumita W; Sato K; Chida T; Okamura N; Moriya K; Koike K
Clin Microbiol Infect; 2007 Dec; 13(12):1204-6. PubMed ID: 17850340
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Biofilm Forming Capability and Antibiotic Resistance in
Egbule OS; Konye OP; Iweriebor BC
Pak J Biol Sci; 2024 Apr; 27(5):268-275. PubMed ID: 38840467
[TBL] [Abstract][Full Text] [Related]
9. Differences in biofilm formation and aggregative adherence between beta-lactam susceptible and beta-lactamases producing P. mirabilis clinical isolates.
Nucleo E; Fugazza G; Migliavacca R; Spalla M; Comelli M; Pagani L; Debiaggi M
New Microbiol; 2010 Jan; 33(1):37-45. PubMed ID: 20402412
[TBL] [Abstract][Full Text] [Related]
10. Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis.
Saito R; Sato K; Kumita W; Inami N; Nishiyama H; Okamura N; Moriya K; Koike K
J Antimicrob Chemother; 2006 Sep; 58(3):673-7. PubMed ID: 16870650
[TBL] [Abstract][Full Text] [Related]
11. Plasmid-mediated multiple antibiotic resistance in Proteus mirabilis isolated from patients with urinary tract infection.
Khan AU; Musharraf A
Med Sci Monit; 2004 Nov; 10(11):CR598-602. PubMed ID: 15507850
[TBL] [Abstract][Full Text] [Related]
12. [Antimicrobial susceptibility of Proteus mirabilis urinary tract isolates from 1999 to 2005 at Nîmes University Hospital].
Mahamat A; Lavigne JP; Bouziges N; Daurès JP; Sotto A
Pathol Biol (Paris); 2006; 54(8-9):456-61. PubMed ID: 17030456
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Proteus mirabilis distribution in multi-species biofilms on urinary catheters and determination of bacteria resistance to antimicrobial agents.
Moryl M; Torzewska A; Jałmuzna P; Rózalski A
Pol J Microbiol; 2013; 62(4):377-84. PubMed ID: 24730132
[TBL] [Abstract][Full Text] [Related]
14. Biofilm Formation and Immunomodulatory Activity of Proteus mirabilis Clinically Isolated Strains.
Fusco A; Coretti L; Savio V; Buommino E; Lembo F; Donnarumma G
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212280
[TBL] [Abstract][Full Text] [Related]
15. Resistance to ciprofloxacin by enhancement of antioxidant defenses in biofilm and planktonic Proteus mirabilis.
Aiassa V; Barnes AI; Albesa I
Biochem Biophys Res Commun; 2010 Feb; 393(1):84-8. PubMed ID: 20097163
[TBL] [Abstract][Full Text] [Related]
16. The assessment of Proteus mirabilis susceptibility to ceftazidime and ciprofloxacin and the impact of these antibiotics at subinhibitory concentrations on Proteus mirabilis biofilms.
Kwiecińska-Piróg J; Skowron K; Zniszczol K; Gospodarek E
Biomed Res Int; 2013; 2013():930876. PubMed ID: 24151628
[TBL] [Abstract][Full Text] [Related]
17. Proteus mirabilis urinary tract infection and bacteremia: risk factors, clinical presentation, and outcomes.
Chen CY; Chen YH; Lu PL; Lin WR; Chen TC; Lin CY
J Microbiol Immunol Infect; 2012 Jun; 45(3):228-36. PubMed ID: 22572004
[TBL] [Abstract][Full Text] [Related]
18. [Drug resistance and proticinogenic types of Proteus mirabilis isolated from urinary tract infections].
Szymaniak L; Aleksandrowicz I; Giedrys-Kalemba S
Med Dosw Mikrobiol; 1999; 51(3-4):323-30. PubMed ID: 10803261
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Urease Enzyme Production and some Other Virulence Factors Expression in Proteus mirabilis by N-Acetyl Cysteine and Dipropyl Disulphide.
Abdel-Baky RM; Ali MA; Abuo-Rahma GEAA; AbdelAziz N
Adv Exp Med Biol; 2017; 973():99-113. PubMed ID: 28190143
[TBL] [Abstract][Full Text] [Related]
20. Catalase Activity is Critical for Proteus mirabilis Biofilm Development, Extracellular Polymeric Substance Composition, and Dissemination during Catheter-Associated Urinary Tract Infection.
White AN; Learman BS; Brauer AL; Armbruster CE
Infect Immun; 2021 Sep; 89(10):e0017721. PubMed ID: 34280035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
